Modality
siRNA
MOA
BCL-2i
Target
AuroraA
Pathway
Ferroptosis
LNMDSCervical Ca
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
~Jan 2023
→ ~Apr 2024
Phase 2
Jul 2024
→ Dec 2031
Phase 2Current
NCT04588426
2,682 pts·MDS
2024-07→2031-12·Terminated
2,682 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-027mo agoAdCom· LN
2031-12-255.7y awayPh3 Readout· MDS
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
Catalysts
AdCom
2025-09-02 · 7mo ago
LN
Ph3 Readout
2031-12-25 · 5.7y away
MDS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04588426 | Phase 2/3 | MDS | Terminated | 2682 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |